These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35420281)

  • 1. Proprotein convertase subtilisin kexin type 9 and main artery atherosclerosis in patients with arterial hypertension.
    Vukolova Y; Gubareva I; Galati G; Germanova O
    Minerva Cardiol Angiol; 2023 Apr; 71(2):129-134. PubMed ID: 35420281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease.
    Aydogan Baykara R; Yilmaz PD; Göktepe MH; Kadiyoran C; Ogul M; Kucuk A; Cumhur Cüre M; Cüre E
    Clin Exp Hypertens; 2022 Jul; 44(5):480-486. PubMed ID: 35502687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
    Chan DC; Pang J; McQuillan BM; Hung J; Beilby JP; Barrett PH; Watts GF
    Heart Lung Circ; 2016 May; 25(5):520-5. PubMed ID: 26706651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
    Ferraz-Amaro I; Delgado-Frías E; Hernández-Hernández V; Sánchez-Pérez H; de Armas-Rillo L; García-Dopico JA; Díaz-González F
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):18-24. PubMed ID: 32324120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
    Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
    Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
    de Armas-Rillo L; Quevedo-Abeledo JC; de Vera-González A; González-Delgado A; García-Dopico JA; Jimenez-Sosa A; Rodríguez-Lozano C; González-Gay MA; Ferraz-Amaro I
    Rheumatology (Oxford); 2021 May; 60(5):2296-2306. PubMed ID: 33295631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
    Liu A; Rahman M; Hafström I; Ajeganova S; Frostegård J
    Lupus; 2020 Jul; 29(8):825-835. PubMed ID: 32479241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.
    Lee CJ; Lee YH; Park SW; Kim KJ; Park S; Youn JC; Lee SH; Kang SM; Jang Y
    Metabolism; 2013 Jun; 62(6):845-50. PubMed ID: 23380568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
    Dalgic Y; Abaci O; Kocas C; Cetinkal G; Dalgic SN; Buyuk A; Ser OS; Batit S; Arat A; Gurmen AT
    Coron Artery Dis; 2020 Jan; 31(1):81-86. PubMed ID: 31206403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
    Panahi Y; Ghahrodi MS; Jamshir M; Safarpour MA; Bianconi V; Pirro M; Farahani MM; Sahebkar A
    Clin Biochem; 2019 Dec; 74():12-18. PubMed ID: 31493378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Level of Proprotein Convertase Subtilisin/Kexin Type 9 with Intima-Media Thickness in Patients with Familial Hypercholesterolemia.
    Benimetskaya KS; Ragino YI; Shakhtshneider EV; Makarenkova KV; Shchepina YV; Stakhneva EM; Voevoda MI
    Bull Exp Biol Med; 2017 Jun; 163(2):199-202. PubMed ID: 28726204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
    Chao TH; Chen IC; Li YH; Lee PT; Tseng SY
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.